Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 7/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30643052 | 0.87 | POLB (0.62) | POLBKMT2AMAPTTP53ALDH1A1 | |
| SCHEMBL13910970 | 0.87 | POLB (0.64) | POLBKMT2AMAPTTP53ALDH1A1 | |
| SCHEMBL5084426 | 0.87 | AKR1B1 (0.69) | POLBKMT2AMAPTTP53ALDH1A1 | |
| SCHEMBL30225130 | 0.81 | AKR1B1 (0.76) | KMT2AMAPTALDH1A1HPGDAKR1B1 | |
| SCHEMBL5188789 | 0.81 | AKR1B1 (0.76) | KMT2AMAPTALDH1A1HPGDAKR1B1 | |
| SCHEMBL8116101 | 0.81 | AKR1B1 (0.55) | POLBKMT2AALDH1A1AKR1B1MEN1 | |
| SCHEMBL8117451 | 0.80 | AKR1B1 (0.78) | POLBKMT2AMAPTTP53GAA | |
| SCHEMBL30224951 | 0.80 | MAOB (0.53) | KMT2AALDH1A1AKR1B1KDM4E | |
| SCHEMBL8827792 | 0.80 | KDM4E (0.78) | POLBKMT2AMAPTTP53ALDH1A1 | |
| SCHEMBL8115159 | 0.78 | AKR1B1 (0.49) | POLBKMT2AALDH1A1AKR1B1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358915-B2 | METTL3 inhibitory compounds | STORM Therapeutics Ltd. (GB) | 2025-07-15 | — | — | US | disclosed |
| CN-116940562-A | Acetamido-phenylbenzamide derivatives and methods of use thereof | 希华医药有限公司 | 2023-10-24 | — | — | CN | disclosed |
| US-20230085408-A1 | METTL3 INHIBITORY COMPOUNDS | STORM THERAPEUTICS LIMITED (GB) | 2023-03-16 | — | — | US | disclosed |
| EP-0634409-B1 | Process of producing 2-cyano-4-oxo-4H-benzopyran compounds | SUMITOMO CHEMICAL CO (JP) | 2000-04-26 | — | — | EP | disclosed |
| US-5659051-A | Process of producing 2-cyano-4-oxo-4H-benzopyran compounds | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1997-08-19 | — | — | US | disclosed |
| EP-0634409-A1 | Process of producing 2-cyano-4-oxo-4H-benzopyran compounds | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1995-01-18 | — | — | EP | disclosed |
| US-5082849-A | Antiinflammatory agents or antiallergens | AVENTIS PHARMACEUTICALS INC. | 1992-01-21 | — | — | US | disclosed |
| EP-0434827-A4 | QUINOLINYL-BENZOPYRAN DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D 4? | — | 1992-01-08 | — | — | EP | disclosed |
| EP-0434827-A1 | QUINOLINYL-BENZOPYRAN DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D 4? | RORER INTERNATIONAL (HOLDINGS), INC. (US) | 1991-07-03 | — | — | EP | disclosed |
| WO-1991001123-A2 | QUINOLINYL-BENZOPYRAN DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D¿4? | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1991-02-07 | — | — | WO | disclosed |
| US-4977162-A | Quinolinyl-chromone derivatives and use for treatment of hypersensitive ailments | RORER PHARMACEUTICAL CORPORATION (US) | 1990-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12358915-B2 | METTL3 inhibitory compounds | METTL3, METTL16, DIMT1 | POLB 1183/4885KMT2A 110/4885MAPT 3077/4885 |
| US-20230085408-A1 | METTL3 INHIBITORY COMPOUNDS | METTL3, METTL16, DIMT1 | POLB 1183/4885KMT2A 110/4885MAPT 3077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.